Menu
Signature Biologics’ mission is to use innovative techniques to manufacture human cellular and biologic products. Proven through rigorous scientific and clinical study, we provide best-in-class development and manufacturing facilities to support production of cellular therapeutics that enhance patients’ lives.
Born from decades of international leadership, Signature Biologics’ vision is to become the premier, trusted source of cellular and biologic therapeutic solutions for the globe, characterized by the highest manufacturing standards.
ISO 9001:2015 specifies requirements for a quality management system when an organization needs to demonstrate an ability to consistently provide products and services that meet customer and regulatory standards. Signature Biologics’ quality management system is ISO certified and surpasses regulatory requirements to meet our own high quality standards.
The American Association of Tissue Banks (AATB) is a professional, non-profit, scientific and educational organization that requires a rigorous set of criteria be met for AATB-accreditation. Signature Biologics is accredited for numerous tissue processing techniques and procedures. Our accreditation number and list of accreditations can be found by clicking the link below.
Current Good Manufacturing Practices (cGMP) and Current Good Tissue Practice (cGTP) employed at Signature Biologics assure that the products are of consistent quality, free from contamination, and protect the recipient from harm. These practices also ensure that staff is well trained, documentation is thorough, and numerous quality checks are performed during the manufacturing process.
PhD in Health Sciences from the Medical University of the Americas
Founded Signature Biologics in 2018 with more than 30 years of experience in applied stem cell research.
One of the earliest pioneer and expert in applied stem cell research and founder of 5 intercontinental companies that specialize in various biomedical products ranging from the use of adult stem cells in Panama to human umbilical cord tissue products produced in the US.
Technology Entrepreneurship and Management Graduate Certificate at UTSA; M.S and Ph.D. Biomedical Engineering at UT San Antonio/ UT Health San Antonio
Joined Signature Biologics in 2021 and is responsible for Technology Transfer, which includes involvement in all steps pertinent to clinical translation, from scientific discovery to clinical translation and regulatory approval.
Over 10 years of experience in cellular and regenerative medicine research and extensive experience in start-up companies focused on biomedical technologies. Dr. Coronado has filed multiple patent applications in biotech and has founded several biomedical companies in an effort to challenge the status quo of medicine by bringing better medical solutions to patients.
Masters of Education
from Columbia University
Joined Signature Biologics in 2019 and is responsible for HR leadership and administration, various operational projects, and executive team support.
Over 17 years of experience in HR, consulting and operations. Prior to current role, worked with individual financial advisors to build enterprise value through practice management structures and the development of multigenerational enterprise teams. Held leadership positions in multiple industries; including non-profit, as Executive Director of PlaySmart, in education, as Collaboration Coordinator for Economic Opportunity at the Skandarlaris Center for Entrepreneurial Studies at Washington University in Saint Louis, and in various corporations.
BS in Biotechnology from Universidad San Martin de Panama; MBA in Project Management Universidad Latina de Panama
Joined Signature Biologics in 2018 and is responsible for laboratory manufacturing operations and compliance with applicable regulations and standards.
Over 10 years in the regenerative medicine industry using adult stem cells starting in MediStem Panama, working in the Production Department as a Laboratory Technician and Cell Line Coordinator. Well experienced in implementation of Quality Management System (QMS) after 6 years in MediStem Panama in the role of Quality Assurance.
He is co-founder and chief science officer of the Riordan Medical Institute (RMI). Located in the Dallas-Fort Worth area city of Southlake, Texas, RMI specializes in the treatment of orthopedic conditions with autologous bone marrow-derived stem cells combined with amniotic tissue products developed by Dr. Riordan.
He is also the founder of Aidan Products, which provides health care professionals with quality nutraceuticals. Dr. Riordan’s team developed the product Stem-Kine, the only nutritional supplement that is clinically proven to increase the amount of circulating stem cells in the body for an extended period of time. Stem-Kine is currently sold in 35 countries.
Dr. Riordan has published more than 70 scientific articles in international peer-reviewed journals. In the stem cell arena, his colleagues and he have published more than 20 articles on multiple sclerosis, spinal cord injury, heart failure, rheumatoid arthritis, Duchenne muscular dystrophy, autism, and Charcot-Marie-Tooth syndrome. In 2007, Dr. Riordan’s research team was the first to discover and document the existence of mesenchymal-like stem cells in menstrual blood. For this discovery, his team was honored with the “Medical Article of the Year Award” from Biomed Central. Other notable journals in which Dr. Riordan has published articles include the British Journal of Cancer, Cellular Immunology, Journal of Immunotherapy, and Translational Medicine.
In addition to his scientific journal publications, Dr. Riordan has authored two books about mesenchymal stem cell therapy: Stem Cell Therapy: A Rising Tide: How Stem Cells Are Disrupting Medicine and Transforming Lives and MSC (Mesenchymal Stem Cells): Clinical Evidence Leading Medicine’s Next Frontier. Dr. Riordan has also written two scientific book chapters on the use of non-controversial stem cells from placenta and umbilical cord.
Dr. Riordan is an established inventor. He is the inventor or co-inventor on more than 25 patent families, including 11 issued patents. His team collaborates with a number of universities and institutions, including National Institutes of Health, Indiana University, University of California, San Diego, University of Utah, University of Western Ontario, and University of Nebraska.
He has made a number of novel discoveries in the field of cancer research since the mid-1990s when he collaborated with his father, Dr. Hugh Riordan, on the effects of high-dose intravenous vitamin C on cancer cells and the tumor microenvironment. This pioneering study on vitamin C’s preferential toxicity to cancer cells notably led to a 1997 patent for the treatment of cancer with vitamin C. In 2010, Dr. Riordan was granted an additional patent for a new cellular vaccine for cancer patients.
Neil Riordan, PA, PhD earned his Bachelor of Science at Wichita State University and graduated summa cum laude. He received his Master’s degree at the University of Nebraska Medical Center. Dr. Riordan completed his education by earning a Ph.D. in Health Sciences at Medical University of the Americas.
